• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Most COVID Trials Ignore Gender Despite Differences in Disease Impact

Most COVID Trials Ignore Gender Despite Differences in Disease Impact

July 19, 2021

Most COVID-19 trials fail to take gender into account in their design and data analysis despite the virus’s different effect on men and women, a new study reports.

The majority of the 4,420 trials studied (66.7 percent) made no mention of gender in the information they submitted to ClinicalTrials.gov, and only 5.4 percent of the trials planned to have gender-matched or representative subgroups and samples, according to the analysis published this month in Nature Communications. In addition, the researchers found that 21 percent of trials only took gender into account when choosing trial participants and only 4 percent planned to use gender as a variable in their analyses.

The team of Danish and Dutch researchers representing Aarhus University, the University of Bielefeld, the University of Copenhagen and Radboud University Medical Center theorized that the intense time pressures the pandemic posed on trials could have been initially to blame for the low numbers of gender considerations in research. But as the pandemic played out and more was learned about the disease’s differing effects on men and women, the focus hardly shifted.

Stressing the importance of accounting for gender in clinical trials, the researchers called the consideration of the differences “an essential step toward more personalized healthcare” and warned that failure to do so may lead to unforeseen, serious side effects later.

Read the full study here: https://go.nature.com/36DJUVB.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing